Andra AP fonden Buys 463,991 Shares of Bristol Myers Squibb Company $BMY

Andra AP fonden grew its stake in shares of Bristol Myers Squibb Company (NYSE:BMY) by 65.1% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,176,900 shares of the biopharmaceutical company’s stock after buying an additional 463,991 shares during the quarter. Bristol Myers Squibb accounts for 0.7% of Andra AP fonden’s investment portfolio, making the stock its 25th biggest position. Andra AP fonden owned 0.06% of Bristol Myers Squibb worth $53,078,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Norges Bank purchased a new position in Bristol Myers Squibb in the 2nd quarter worth $1,554,154,000. Charles Schwab Investment Management Inc. lifted its position in shares of Bristol Myers Squibb by 16.8% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 70,802,680 shares of the biopharmaceutical company’s stock worth $3,277,456,000 after purchasing an additional 10,195,775 shares during the period. Arrowstreet Capital Limited Partnership grew its stake in Bristol Myers Squibb by 428.5% in the second quarter. Arrowstreet Capital Limited Partnership now owns 11,311,281 shares of the biopharmaceutical company’s stock worth $523,599,000 after purchasing an additional 9,171,098 shares during the period. Man Group plc grew its holdings in Bristol Myers Squibb by 280.4% in the second quarter. Man Group plc now owns 7,465,845 shares of the biopharmaceutical company’s stock worth $345,594,000 after purchasing an additional 5,503,391 shares during the period. Finally, Franklin Resources Inc. increased its stake in shares of Bristol Myers Squibb by 142.8% during the second quarter. Franklin Resources Inc. now owns 8,436,811 shares of the biopharmaceutical company’s stock valued at $390,541,000 after purchasing an additional 4,961,869 shares in the last quarter. 76.41% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Positive Phase III interim topline results reported for izalontamab brengitecan (Iza‑bren) in previously treated unresectable locally advanced/metastatic triple‑negative breast cancer — a potentially high-value ADC Bristol Myers licensed from China that management has flagged as central to future growth. This outcome materially de‑riskes a late‑stage asset that could drive long‑term revenue and milestone upside. SystImmune and Bristol Myers Squibb Highlight Positive Phase III Interim Topline Results for izalontamab brengitecan (Iza‑bren)
• Positive Sentiment: Clinical pipeline progress beyond Iza‑bren: BMY advanced a pediatric lymphoma combination study, signaling additional, smaller near‑term clinical catalysts and “quiet upside” opportunities that can support incremental valuation gains if data readouts continue to be constructive. Bristol‑Myers Squibb Advances Pediatric Lymphoma Combo
• Neutral Sentiment: Positive press pieces from stock‑style outlets (Zacks) highlight BMY as a value and momentum name, which may attract different investor audiences but do not represent new company fundamentals or catalysts. Bristol Myers Squibb (BMY) is a Top‑Ranked Momentum Stock
• Negative Sentiment: RBC Capital initiated coverage with a Sector Perform rating and a $60 price target — slightly below current levels — which can temper upside from momentum traders and suggests limited near‑term upside in RBC’s view. RBC Capital Initiates Bristol Myers with $60 Target
• Negative Sentiment: Recent quarterly results showed an EPS miss (Q4 EPS $1.26 vs. $1.65 expected) despite a slight revenue beat; management set FY2026 EPS guidance of $6.05–$6.35. The earnings miss and the still‑high leverage (debt/equity ~2.3) remain near‑term headwinds that can pressure the stock until growth visibility improves. Bristol Myers Squibb – recent earnings and metrics

Wall Street Analysts Forecast Growth

BMY has been the subject of a number of analyst reports. Royal Bank Of Canada initiated coverage on shares of Bristol Myers Squibb in a report on Tuesday. They issued a “sector perform” rating and a $60.00 target price for the company. Barclays assumed coverage on shares of Bristol Myers Squibb in a research note on Thursday, February 19th. They set an “overweight” rating and a $75.00 target price on the stock. HSBC reissued a “hold” rating and issued a $53.00 target price on shares of Bristol Myers Squibb in a research report on Wednesday, December 10th. Scotiabank reaffirmed a “sector perform” rating and set a $60.00 target price (up from $53.00) on shares of Bristol Myers Squibb in a report on Friday, January 9th. Finally, Truist Financial set a $65.00 price target on shares of Bristol Myers Squibb in a research note on Wednesday, December 3rd. Nine analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Bristol Myers Squibb currently has an average rating of “Hold” and a consensus price target of $60.71.

Bristol Myers Squibb Stock Down 0.3%

Shares of BMY opened at $61.10 on Friday. The company has a market capitalization of $124.43 billion, a PE ratio of 17.71, a price-to-earnings-growth ratio of 0.17 and a beta of 0.29. The business’s 50 day moving average is $56.81 and its 200 day moving average is $50.41. Bristol Myers Squibb Company has a 12-month low of $42.52 and a 12-month high of $63.33. The company has a current ratio of 1.26, a quick ratio of 1.14 and a debt-to-equity ratio of 2.32.

Bristol Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 EPS for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.39). The firm had revenue of $12.50 billion for the quarter, compared to the consensus estimate of $12.24 billion. Bristol Myers Squibb had a net margin of 14.64% and a return on equity of 69.65%. The firm’s revenue was up 1.3% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.67 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Research analysts expect that Bristol Myers Squibb Company will post 6.74 earnings per share for the current fiscal year.

Bristol Myers Squibb Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, February 2nd. Stockholders of record on Friday, January 2nd were issued a $0.63 dividend. The ex-dividend date was Friday, January 2nd. This is a positive change from Bristol Myers Squibb’s previous quarterly dividend of $0.62. This represents a $2.52 annualized dividend and a dividend yield of 4.1%. Bristol Myers Squibb’s dividend payout ratio (DPR) is currently 73.04%.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.